Craviso G L, Musacchio J M
Mol Pharmacol. 1983 May;23(3):629-40.
Binding of dextromethorphan (DM) to guinea pig brain is stereoselective, since levomethorphan is 20 times weaker than DM in competing for DM sites. In general, opiate agonists and antagonists as well as their corresponding dextrorotatory isomers are weak competitors for tritiated dextromethorphan ([3H]DM) binding sites and display IC50 values in the micromolar range. In contrast, several non-narcotic, centrally acting antitussives are inhibitory in the nanomolar range (IC50 values for caramiphen, carbetapentane, dimethoxanate, and pipazethate are 25 nM, 9 nM, 41 nM, and 190 nM, respectively). Other antitussives, such as levopropoxyphene, chlophedianol, and fominoben, have poor affinity for DM sites whereas the antitussive noscapine enhances DM binding by increasing the affinity of DM for its central binding sites. Additional competition studies indicate that there is no correlation of DM binding with any of the known or putative neurotransmitters in the central nervous system. DM binding is also not related to tricyclic antidepressant binding sites or biogenic amine uptake sites. However, certain phenothiazine neuroleptics and typical and atypical antidepressants inhibit binding with IC50 values in the nanomolar range. Moreover, the anticonvulsant drug diphenylhydantoin enhances DM binding in a manner similar to that of noscapine. Preliminary experiments utilizing acid extracts of brain have not demonstrated the presence of an endogenous ligand for DM sites. The binding characteristics of DM sites studied in rat and mouse brain indicate that the relative potencies of several antitussives to inhibit specific DM binding vary according to species. High-affinity, saturable, and stereoselective [3H]DM binding sites are present in liver homogenates, but several differences have been found for these peripheral binding sites and those described for brain. Although the nature of central DM binding sites is not known, the potent interaction of several classes of centrally acting antitussives with DM sites suggests that they may be related to the mechanism of action of this drug.
右美沙芬(DM)与豚鼠脑的结合具有立体选择性,因为左美沙芬在竞争DM位点方面比DM弱20倍。一般来说,阿片类激动剂和拮抗剂以及它们相应的右旋异构体是氚标记右美沙芬([3H]DM)结合位点的弱竞争者,其IC50值在微摩尔范围内。相比之下,几种非麻醉性中枢性镇咳药在纳摩尔范围内具有抑制作用(卡马芬、卡比沙明、地美索酯和哌齐特的IC50值分别为25 nM、9 nM、41 nM和190 nM)。其他镇咳药,如左丙氧芬、氯苯达诺和福米诺苯,对DM位点的亲和力较差,而镇咳药那可丁通过增加DM对其中枢结合位点的亲和力来增强DM结合。额外的竞争研究表明,DM结合与中枢神经系统中任何已知或假定的神经递质均无相关性。DM结合也与三环类抗抑郁药结合位点或生物胺摄取位点无关。然而,某些吩噻嗪类抗精神病药以及典型和非典型抗抑郁药在纳摩尔范围内以IC50值抑制结合。此外,抗惊厥药物苯妥英钠以类似于那可丁的方式增强DM结合。利用脑酸提取物进行的初步实验未证明存在DM位点的内源性配体。在大鼠和小鼠脑中研究的DM位点的结合特性表明,几种镇咳药抑制特异性DM结合的相对效力因物种而异。肝匀浆中存在高亲和力、可饱和且立体选择性的[3H]DM结合位点,但已发现这些外周结合位点与脑结合位点存在一些差异。尽管中枢DM结合位点的性质尚不清楚,但几类中枢性镇咳药与DM位点的强效相互作用表明它们可能与该药物的作用机制有关。